secwatch.observer — SEC 8-K summary
======================================

Issuer:     TITAN PHARMACEUTICALS INC (—)
CIK:        0000910267
Form:       8-K
Filed at:   2025-01-08T23:59:59+00:00
Accession:  0001829126-25-000119
Event type: regulatory
Sentiment:  negative
Materiality: 0.50
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Titan Pharmaceuticals receives Nasdaq notice for failure to hold annual shareholder meeting; faces potential delisting
--------------------------------------------------------------------------------

- Received Nasdaq notice on Jan 3, 2025 for noncompliance with listing rules due to missing annual shareholder meeting within 12 months of fiscal year end.
- Has 45 days to submit a compliance plan; if accepted, Nasdaq may grant exception until June 30, 2025 to regain compliance.
- Failure to regain compliance could result in delisting of common stock from Nasdaq Capital Market.
- Company intends to schedule annual meeting and submit plan to regain compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/910267/000182912625000119/0001829126-25-000119-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/910267/000182912625000119/titanpharma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-25-000119

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer